Cover Image
市场调查报告书

5-Hydroxytryptamine(血清素)受体2B:开发中产品分析

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品编码 520780
出版日期 内容信息 英文 50 Pages
订单完成后即时交付
价格
Back to Top
5-Hydroxytryptamine(血清素)受体2B:开发中产品分析 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Pipeline Review, H1 2018
出版日期: 2018年06月12日 内容信息: 英文 50 Pages
简介

本报告提供以5-Hydroxytryptamine(血清素)受体2B为标的之治疗药开发平台现状及最新更新之各开发阶段比较分析,提供涵括了最新的新闻和发表之企业和研究机关开发中治疗药,治疗药评估,后期阶段及中止的计划等相关信息。

简介

  • 调查范围

5-Hydroxytryptamine(血清素)受体2B ;概要

5-Hydroxytryptamine(血清素)受体2B ;治疗药的开发

  • 开发中的产品:各开发阶段
  • 开发中的产品:各治疗领域
  • 开发中的产品:不同症状
  • 企业开发中的产品
  • 大学/研究机关开发中的产品

治疗药的评估

  • 各作用机制
  • 各给药途径
  • 各分子类型

开发治疗药的企业

  • AnaMar AB
  • Astellas Pharma Inc.
  • Biofrontera AG
  • Neurim Pharmaceuticals Ltd
  • RaQualia Pharma Inc
  • Reviva Pharmaceuticals Inc

药物简介

暂停中的产品

开发中止的产品

产品开发的里程碑

  • 主要消息和新闻稿

附录

图表

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC1498TDB

Summary

According to the recently published report '5-Hydroxytryptamine Receptor 2B - Pipeline Review, H1 2018'; 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - 5-Hydroxytryptamine receptor 2B (5-HT2B) or serotonin receptor 2B is a protein encoded by the HTR2B gene. It plays a role in the regulation of behavior, including impulsive behavior. It protects cardiomyocytes against apoptosis. It plays a role in the adaptation of pulmonary arteries to chronic hypoxia and vasoconstriction.

The report '5-Hydroxytryptamine Receptor 2B - Pipeline Review, H1 2018' outlays comprehensive information on the 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal, Immunology, Respiratory, Metabolic Disorders, Musculoskeletal Disorders, Oncology and Ophthalmology which include indications Drug Addiction, Attention Deficit Hyperactivity Disorder (ADHD), Idiopathic Pulmonary Fibrosis, Psychosis, Pulmonary Arterial Hypertension, Schizophrenia, Systemic Sclerosis (Scleroderma), Alzheimer's Disease, Autism, Binge Eating Disorder, Bipolar Disorder (Manic Depression), Cirrhosis, Diarrhea, Fibrosis, Insomnia, Irritable Bowel Syndrome, Liver Fibrosis, Major Depressive Disorder, Migraine, Neuroendocrine Tumors, Non-Alcoholic Steatohepatitis (NASH), Obesity, Obsessive-Compulsive Disorder, Ocular Hypertension, Open-Angle Glaucoma, Psychiatric Disorders, Psychological Disorders, Schizoaffective Disorder and Sedation.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B)
  • The report reviews 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics and enlists all their major and minor projects
  • The report assesses 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Overview
  • 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Companies Involved in Therapeutics Development
  • AnaMar AB
  • Astellas Pharma Inc
  • Neurim Pharmaceuticals Ltd
  • RaQualia Pharma Inc
  • Reviva Pharmaceuticals Inc
  • 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Drug Profiles
  • AM-1476 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DDD-024 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • INV-240 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • piromelatine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RP-5063 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RQ-00310941 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SERx-480 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize HTR2B for Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for Migraine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Target 5HT2 for CNS Disorders and Obesity - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • terguride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Dormant Products
  • 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Discontinued Products
  • 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Product Development Milestones
  • Featured News & Press Releases
  • Apr 10, 2018: Reviva Pharmaceuticals Receives FDA Orphan Designation for RP5063 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
  • Oct 17, 2017: Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the Treatment of Pulmonary Arterial Hypertension
  • Mar 07, 2017: Phase II Clinical Trial for Treatment of Mild Alzheimer's Disease
  • Nov 17, 2016: Reviva Pharmaceuticals Receives FDA Orphan Designation for Pulmonary Arterial Hypertension (PAH)
  • Sep 28, 2016: Neurim Pharmaceuticals Announces First Patients Enrollments in ReCOGNITION - Phase II Clinical Trial of Piromelatine for Mild Alzheimers Disease
  • May 19, 2016: Reviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results for Pulmonary Arterial Hypertension at the American Thoracic Society Conference 2016
  • Apr 20, 2016: RaQualia Receives a Patent Allowance for 5-HT 2B Antagonist in Korea
  • Oct 22, 2015: Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for Memory Deficits
  • Jun 01, 2015: RaQualia to Initiate Phase I Clinical Trial for 5-HT2B Antagonist in UK
  • Aug 20, 2014: RaQualia Receives a Patent Allowance for 5-HT2B Antagonist in Japan
  • Nov 05, 2013: Reviva Pharmaceuticals Announces Successful End-of-Phase 2 Meeting With FDA for RP5063
  • Jul 11, 2013: Novel antipsychotic shows early promise
  • Apr 09, 2013: Reviva Pharma Reports Positive Top-Line Results From Phase II Study Of RP5063 For Treatment Of Schizophrenia And Schizoaffective Disorder
  • Feb 18, 2013: Neurim Pharma Announces Positive Phase II Clinical Trial Results Of Piromelatine For Treatment Of Insomnia
  • Jan 14, 2013: Reviva Pharma Completes Patient Enrollment In Phase II Trial Of RP5063 For Treatment Of Schizophrenia And Schizoaffective Disorder
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indications, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by AnaMar AB, H1 2018
  • Pipeline by Astellas Pharma Inc, H1 2018
  • Pipeline by Neurim Pharmaceuticals Ltd, H1 2018
  • Pipeline by RaQualia Pharma Inc, H1 2018
  • Pipeline by Reviva Pharmaceuticals Inc, H1 2018
  • Dormant Products, H1 2018
  • Dormant Products, H1 2018 (Contd..1), H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
Back to Top